Compare HUBG & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUBG | LMAT |
|---|---|---|
| Founded | 1971 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 1996 | 2006 |
| Metric | HUBG | LMAT |
|---|---|---|
| Price | $25.71 | $84.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 8 |
| Target Price | $37.17 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 976.3K | 219.3K |
| Earning Date | 11-06-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.89% | 1.17% |
| EPS Growth | N/A | ★ 30.57 |
| EPS | 1.34 | ★ 1.42 |
| Revenue | ★ $3,946,390,000.00 | $249,602,000.00 |
| Revenue This Year | N/A | $10.79 |
| Revenue Next Year | $1.45 | $9.54 |
| P/E Ratio | ★ $19.79 | $60.15 |
| Revenue Growth | N/A | ★ 13.53 |
| 52 Week Low | $25.50 | $78.22 |
| 52 Week High | $53.26 | $118.01 |
| Indicator | HUBG | LMAT |
|---|---|---|
| Relative Strength Index (RSI) | 30.73 | 57.93 |
| Support Level | N/A | $84.33 |
| Resistance Level | $27.61 | $88.54 |
| Average True Range (ATR) | 1.10 | 2.12 |
| MACD | 0.28 | 0.50 |
| Stochastic Oscillator | 18.89 | 84.76 |
Hub Group ranks among the largest providers of rail intermodal service. Approximately 60% of consolidated revenue comes from Hub's intermodal and transportation solutions division. ITS includes its flagship intermodal operations, which use the Class I rail carriers for the underlying line-haul movement of containers, as well as its dedicated truckload shipping unit. Hub's logistics segment includes its asset-light truck brokerage operations along with its outsourced transportation management, warehousing and fulfillment, and heavy-goods final mile delivery offerings. Hub often makes tuck-in acquisitions that expand its brokerage, last-mile, and dedicated offerings.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.